Source Paper
Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease
Melissa K. McCoy, Terina N. Martinez, Kelly A. Ruhn, David E. Szymkowski, Christine G. Smith et al.
Journal of Neuroscience • 2006
LPS Nigral Infusion Model
Objective: To evaluate the role of soluble TNF in nigral degeneration by chronic in vivo coinfusion of bacterial lipopolysaccharide (LPS) into the substantia nigra to induce neuroinflammation and assess neuroprotective effects of TNF inhibition
This is a LPS Nigral Infusion Model protocol using rat as the model organism. The procedure involves 5 procedural steps, 2 equipment items, 4 materials. Extracted from a 2006 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified in provided text • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
Prepare XENP345 and LPS for coinfusion • Perform nigral infusion surgery • Initiate chronic coinfusion
Primary readouts
- Extent of retrograde nigral degeneration
- Amphetamine-induced rotational behavior
- Striatal dopamine levels
- Selective degeneration of dopaminergic neurons
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Prepare XENP345 and LPS for coinfusion
Prepare the engineered dominant-negative TNF compound XENP345 and bacterial lipopolysaccharide (LPS) for chronic in vivo coinfusion into the substantia nigra
Note: XENP345 is a PEGylated version of TNF variant A145R/I97T
View evidence from paper
“chronic in vivo coinfusion of XENP345 with bacterial lipopolysaccharide (LPS) into the substantia nigra”
Perform nigral infusion surgery
Conduct stereotaxic surgery to implant infusion cannula into the substantia nigra for chronic coinfusion of XENP345 and LPS
Note: XENP345 was neuroprotective only when infused into the nigra, not the striatum
View evidence from paper
“XENP345 was neuroprotective only when infused into the nigra, not the striatum”
Initiate chronic coinfusion
Begin chronic in vivo coinfusion of XENP345 with bacterial lipopolysaccharide (LPS) into the substantia nigra
Note: This procedure induces neuroinflammation and nigral degeneration
View evidence from paper
“chronic in vivo coinfusion of XENP345 with bacterial lipopolysaccharide (LPS) into the substantia nigra”
Assess amphetamine-induced rotational behavior
Measure amphetamine-induced rotational behavior in rats to assess preservation of striatal dopamine levels
Note: Attenuated rotational behavior indicates preservation of dopaminergic function
View evidence from paper
“XENP345/6-OHDA rats displayed attenuated amphetamine-induced rotational behavior, indicating preservation of striatal dopamine levels”
Analyze nigral degeneration
Evaluate the extent of nigral degeneration and compare between treatment groups receiving XENP345 coinfusion versus LPS alone
Note: Similar protective effects were observed with chronic coinfusion of XENP345 with LPS into substantia nigra
View evidence from paper
“Similar protective effects were observed with chronic in vivo coinfusion of XENP345 with bacterial lipopolysaccharide (LPS) into the substantia nigra”